

Genpact Signs Five-Year Contract Extension with Major Pharmaceutical Company for Finance and Accounting Business Process Management Services

NEW YORK, Jan. 15, 2013 /[PRNewswire](#)/ -- Genpact Limited (NYSE: G), a global leader in business process management and technology services, today announced it has been awarded a five-year contract extension by global pharmaceutical leader GlaxoSmithKline (GSK) for finance and accounting (F&A) services. Under this agreement, Genpact will continue to deliver global services such as accounts payable, record-to-report, and order-to-cash across several global regions, supporting GSK's drive to standardize core business processes and services.

(Logo: <http://photos.prnewswire.com/prnh/20120501/NY98560LOGO>)

Paul Fry, senior vice president for Finance Services in GSK's Core Business Services said, "Our continued partnership with Genpact is a key element in our drive to deliver simpler, more efficient and standardized business processes for GSK."

"Over the last six years, the partnership between Genpact and GSK has been able to address GSK's growing global business and the unique challenges within the pharmaceutical market while improving the outcomes of these end-to-end processes, especially through our Lean and Six Sigma framework," said BK Kalra, senior vice president and business leader, Life Sciences, Genpact. "We are thrilled to expand our valued relationship with GSK and ensure continuous process effectiveness so that their path to future growth is smooth."

Genpact provides business process management and technology services to 8 of the top ten global pharmaceutical companies. Genpact helps them to make their end-to-end F&A processes more effective, address regulatory changes, make use of customer and market data through its analytics services, and improve pharma companies' customer service operations through intelligent technology solutions. More information can be accessed at <http://www.genpact.com/home/industries/life-sciences>.

About GSK

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and

healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

About Genpact

Genpact Limited (NYSE: G), a global leader in business process management and technology services, leverages the power of smarter processes, smarter analytics and smarter technology to help its clients drive intelligence across their enterprise. Genpact's Smart Enterprise Processes (SEPSM) framework, its unique science of process combined with deep domain expertise in multiple industry verticals, leads to superior business outcomes. Genpact's Smart Decision Services deliver valuable business insights to its clients through targeted analytics, reengineering expertise, and advanced risk management. Making technology more intelligent by embedding it with process and data insights, Genpact also offers a wide range of technology services. Driven by a passion for process innovation and operational excellence built on its Lean and Six Sigma DNA and the legacy of serving GE for more than 15 years, the company's 60,500+ professionals around the globe deliver services to its more than 600 clients from a network of 74 delivery centers across 20 countries supporting more than 30 languages. For more information, visit www.genpact.com. Follow Genpact on [Twitter](#), [Facebook](#) and [LinkedIn](#).

For more information:

Gail Marold (<i>Genpact Media Relations</i>) gail.marold@genpact.com +1 919-345-3899	Barbara Tate (<i>For Genpact U.S.</i>) barbara.tate@ogilvy.com +1 212-880-5338	Rupali Kathuria (<i>For Genpact India</i>) rupali.kathuria@bm.com +91 124 441 75
---	---	--

SOURCE Genpact Limited

Additional assets available online: [Photos \(1\)](#)

<https://media.genpact.com/2013-01-15-Genpact-Signs-Five-Year-Contract-Extension-with-Major-Pharmaceutical-Company-for-Finance-and-Accounting-Business-Process-Management-Services>